Trial reportAntimicrobial agents and chemotherapy2010
Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy.
Trial report in Antimicrobial agents and chemotherapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Once-daily darunavir/ritonavir 400/100 mg in triple therapy: efficacy and penetration in seminal compartment in ANRS-165 DARULIGHT study.British journal of clinical pharmacology · 2019Trial
- Contemporary antiretroviral pharmacology in the male genital tract: implications for HIV treatment and prevention.Antimicrobial agents and chemotherapy · 2026Review
- Effect of monotherapy with darunavir/cobicistat on viral load and semen quality of HIV-1 patients.PloS one · 2018Article
- Current application of CRISPR/Cas9 gene-editing technique to eradication of HIV/AIDS.Gene therapy · 2017Review
- Patterns of residual HIV-1 RNA shedding in the seminal plasma of patients on effective antiretroviral therapy.Basic and clinical andrology · 2017Article
- Article
- Article
- Practical guidance for nonoccupational postexposure prophylaxis to prevent HIV infection: an editorial review.AIDS (London, England) · 2014Review
- Review
- Boosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meeting.AIDS research and therapy · 2013Article
- Antiretrovirals and safer conception for HIV-serodiscordant couples.Current opinion in HIV and AIDS · 2012Review
- HIV reservoirs and strategies for eradication.Current HIV/AIDS reports · 2012Review
- Impact of short-term HAART initiated during the chronic stage or shortly post-exposure on SIV infection of male genital organs.PloS one · 2012Article
- Tissue-specific HIV-1 infection: why it matters.Future virology · 2011Article
- Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study).Antimicrobial agents and chemotherapy · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HIV-1 RNA level and darunavir concentration in the genital tract were measured in 45 men receiving darunavir-ritonavir mono- or tritherapy. At week 48, a low frequency (3/45) of HIV-1 RNA shedding was observed in patients (1 on monotherapy and 2 on triple therapy), although they had undetectable HIV-1 RNA in plasma. The median darunavir seminal plasma concentration was close to the blood plasma free fraction, demonstrating a good penetration of darunavir into the male genital tract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.